文献速递流行病学与生物统计新药、器械与细胞基因治疗研发临床试验与 GCP

COVID-19药物治疗比较疗效与安全性的系统综述与网络荟萃分析

Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis.
PubMed 文献 · PLoS Med · 2020-12-30

该研究通过系统综述与网络荟萃分析,纳入110项研究(40项RCT和70项观察性研究),评估住院COVID-19患者药物治疗的相对疗效与安全性。基于RCT,皮质类固醇和瑞德西韦在非ICU中重度患者中降低进展至重症和死亡风险;皮质类固醇还降低ICU危重患者死亡率。观察性研究显示多种药物与死亡率降低相关,但证据确定性普遍较低。

要点

  • 皮质类固醇和瑞德西韦在非ICU中重度患者中降低进展至重症和死亡风险。
  • 皮质类固醇可降低ICU危重患者死亡率。
  • 羟氯喹联合阿奇霉素增加QT延长和致命心脏并发症风险。

核心结论

  • 抗炎药物(皮质类固醇、托珠单抗、阿那白滞素、IVIG)、恢复期血浆和瑞德西韦与住院COVID-19患者结局改善相关。
  • 羟氯喹未提供临床获益,与阿奇霉素联用时存在心脏安全风险,尤其在脆弱人群中。

研究设计与样本

  • 系统综述与网络荟萃分析,纳入110项研究(40项RCT和70项观察性研究)。
  • 研究对象为住院COVID-19患者,排除无需住院的轻症或自限性病程患者。
  • 检索PubMed、Google Scholar、MEDLINE、Cochrane Library、medRxiv、SSRN、WHO ICTRP和ClinicalTrials.gov,时间从2020年初至2020年8月24日。

主要发现

  • 基于RCT,在非ICU中重度患者中,皮质类固醇降低进展至重症风险(OR 0.23,95%CI 0.06-0.86,p=0.032)和死亡风险(OR 0.78,95%CI 0.66-0.91,p=0.002)。
  • 基于RCT,在非ICU中重度患者中,瑞德西韦降低进展至重症风险(OR 0.29,95%CI 0.17-0.50,p<0.001)和死亡风险(OR 0.62,95%CI 0.39-0.98,p=0.041)。
  • 基于RCT,皮质类固醇降低ICU危重患者死亡率(OR 0.54,95%CI 0.40-0.73,p<0.001)。
  • 观察性研究中,干扰素-α、伊托珠单抗、索磷布韦联合达拉他韦、阿那白滞素、托珠单抗和恢复期血浆与非ICU患者死亡率降低相关。
  • 观察性研究中,高剂量IVIG、伊维菌素和托珠单抗与危重患者死亡率降低相关;恢复期血浆与2周病毒清除率改善相关(OR 11.39,95%CI 3.91-33.18,p<0.001)。

关键数值与推荐

  • 仅29%的当前COVID-19药物治疗证据为中等或高确定性,可转化为实践和政策;其余71%为低或极低确定性。
  • 采用GRADE框架评估证据质量;使用RoB2和ROBINS-I框架评估个体研究偏倚风险,总体为低至中等。
  • 研究方案已在PROSPERO注册(CRD42020186527)。

临床怎么用

  • 对于非ICU中重度住院COVID-19患者,可考虑使用皮质类固醇或瑞德西韦以降低进展和死亡风险。
  • 对于ICU危重患者,皮质类固醇可降低死亡率。
  • 应避免对心脏受损人群使用羟氯喹联合阿奇霉素,因其增加QT延长和致命心脏并发症风险。

局限性

  • 总体证据水平较低,降低了推荐的确定性。
  • 观察性研究结果不能推断因果关系,仅提示关联。
  • 个体研究偏倚风险一般为低至中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Numerous clinical trials and observational studies have investigated various pharmacological agents as potential treatment for Coronavirus Disease 2019 (COVID-19), but the results are heterogeneous and sometimes even contradictory to one another, making it difficult for clinicians to determine which treatments are truly effective. METHODS AND FINDINGS: We carried out a systematic review and network meta-analysis (NMA) to systematically evaluate the comparative efficacy and safety of pharmacological interventions and the level of evidence behind each treatment regimen in different clinical settings. Both published and unpublished randomized controlled trials (RCTs) and confounding-adjusted observational studies which met our predefined eligibility criteria were collected. We included studies investigating the effect of pharmacological management of patients hospitalized for COVID-19 management. Mild patients who do not require hospitalization or have self-limiting disease courses were not eligible for our NMA. A total of 110 studies (40 RCTs and 70 observational studies) were included. PubMed, Google Scholar, MEDLINE, the Cochrane Library, medRxiv, SSRN, WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov were searched from the beginning of 2020 to August 24, 2020. Studies from Asia (41 countries, 37.2%), Europe (28 countries, 25.4%), North America (24 countries, 21.8%), South America (5 countries, 4.5%), and Middle East (6 countries, 5.4%), and additional 6 multinational studies (5.4%) were included in our analyses. The outcomes of interest were mortality, progression to severe disease (severe pneumonia, admission to intensive care unit (ICU), and/or mechanical ventilation), viral clearance rate, QT prolongation, fatal cardiac complications, and noncardiac serious adverse events. Based on RCTs, the risk of progression to severe course and mortality was significantly reduced with corticosteroids (odds ratio (OR) 0.23, 95% confidence interval (CI) 0.06 to 0.86, p = 0.032, and OR 0.78, 95% CI 0.66 to 0.91, p = 0.002, respectively) and remdesivir (OR 0.29, 95% CI 0.17 to 0.50, p < 0.001, and OR 0.62, 95% CI 0.39 to 0.98, p = 0.041, respectively) compared to standard care for moderate to severe COVID-19 patients in non-ICU; corticosteroids were also shown to reduce mortality rate (OR 0.54, 95% CI 0.40 to 0.73, p < 0.001) for critically ill patients in ICU. In analyses including observational studies, interferon-alpha (OR 0.05, 95% CI 0.01 to 0.39, p = 0.004), itolizumab (OR 0.10, 95% CI 0.01 to 0.92, p = 0.042), sofosbuvir plus daclatasvir (OR 0.26, 95% CI 0.07 to 0.88, p = 0.030), anakinra (OR 0.30, 95% CI 0.11 to 0.82, p = 0.019), tocilizumab (OR 0.43, 95% CI 0.30 to 0.60, p < 0.001), and convalescent plasma (OR 0.48, 95% CI 0.24 to 0.96, p = 0.038) were associated with reduced mortality rate in non-ICU setting, while high-dose intravenous immunoglobulin (IVIG) (OR 0.13, 95% CI 0.03 to 0.49, p = 0.003), ivermectin (OR 0.15, 95% CI 0.04 to 0.57, p = 0.005), and tocilizumab (OR 0.62, 95% CI 0.42 to 0.90, p = 0.012) were associated with reduced mortality rate in critically ill patients. Convalescent plasma was the only treatment option that was associated with improved viral clearance rate at 2 weeks compared to standard care (OR 11.39, 95% CI 3.91 to 33.18, p < 0.001). The combination of hydroxychloroquine and azithromycin was shown to be associated with increased QT prolongation incidence (OR 2.01, 95% CI 1.26 to 3.20, p = 0.003) and fatal cardiac complications in cardiac-impaired populations (OR 2.23, 95% CI 1.24 to 4.00, p = 0.007). No drug was significantly associated with increased noncardiac serious adverse events compared to standard care. The quality of evidence of collective outcomes were estimated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. The major limitation of the present study is the overall low level of evidence that reduces the certainty of recommendations. Besides, the risk of bias (RoB) measured by RoB2 and ROBINS-I framework for individual studies was generally low to moderate. The outcomes deducted from observational studies could not infer causality and can only imply associations. The study protocol is publicly available on PROSPERO (CRD42020186527). CONCLUSIONS: In this NMA, we found that anti-inflammatory agents (corticosteroids, tocilizumab, anakinra, and IVIG), convalescent plasma, and remdesivir were associated with improved outcomes of hospitalized COVID-19 patients. Hydroxychloroquine did not provide clinical benefits while posing cardiac safety risks when combined with azithromycin, especially in the vulnerable population. Only 29% of current evidence on pharmacological management of COVID-19 is supported by moderate or high certainty and can be translated to practice and policy; the remaining 71% are of low or very low certainty and warrant further studies to establish firm conclusions.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Kim MS, An MH, Kim WJ, et al. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. PLoS Med. 2020. PMID: 33378357. doi:10.1371/journal.pmed.1003501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。